Dual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidases.
Octopamine, which is closely related to norepinephrine, acts as a neurotransmitter in invertebrates and is a trace amine with undefined properties in vertebrates. The octopaminergic receptors identified in insects are targets of various pesticides but are absent in vertebrates. We have established that octopamine stimulates fat cell lipolysis in mammals via activation of beta3-adrenoceptors (ARs), whereas this amine has been described elsewhere as an alpha2-AR agonist and as a substrate for monoamine oxidase (MAO) or semicarbazide-sensitive amine oxidase (SSAO). Because we have recently reported that amine oxidase substrates promote glucose transport in rat and human adipocytes, the in vitro octopamine effects on lipolysis and glucose uptake were reassessed by using adipocytes from beta3-AR-deficient mice. The lipolytic effect and the counter-regulation of insulin action on glucose transport provoked by 0.1 to 1 mM octopamine or by 1 microM beta3-AR agonists found in control animals disappeared in adipocytes from beta3-AR-deficient mice. This revealed an insulin-like effect of octopamine on glucose uptake, which was dependent on its oxidation by MAO or SSAO, as was the case for tyramine and benzylamine, devoid of beta3-adrenergic agonism. Similarly, octopamine promoted glucose transport in human adipocytes and exhibited a weaker lipolytic stimulation than in rodent adipocytes. These findings indicate that, besides its lipolytic activity, octopamine exerts, at millimolar dose, dual effect on glucose transport in adipocytes: counteracting insulin action via beta3-AR activation and stimulating basal transport via its oxidation by MAO or SSAO.
Visentin
V
V
Institut National de la Santé et de la Recherche Médicale, Toulouse, France.
Morin
N
N
Fontana
E
E
Prévot
D
D
Boucher
J
J
Castan
I
I
Valet
P
P
Grujic
D
D
Carpéné
C
C
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism*; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D058667:Adrenergic beta-3 Receptor Agonists; D006631:Amine Oxidase (Copper-Containing) / Q000378:metabolism; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D002469:Cell Separation; D002478:Cells, Cultured; D005947:Glucose / Q000378:metabolism*; D006601:Hexoses / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008066:Lipolysis / Q000187:drug effects; D051379:Mice; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009655:Octopamine / Q000494:pharmacology*; D010084:Oxidation-Reduction; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000378:metabolism*; D014439:Tyramine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D058667:Adrenergic beta-3 Receptor Agonists; D001596:Benzylamines; D006601:Hexoses; D008996:Monoamine Oxidase Inhibitors; D009655:Octopamine; D006631:Amine Oxidase (Copper-Containing); D008995:Monoamine Oxidase; D000587:Oxidoreductases Acting on CH-NH Group Donors; D005947:Glucose; D014439:Tyramine